Data presented at the 2016 annual meeting of the American College of Gastroenterology reveals how costly inpatient treatment of Inflammatory Bowel Disease (IBD) has become. The total mean charge for hospitalized IBD patients rose from $23,690 in 2004 to $39,373 in 2013. The data comprised inpatient data from all states participating in the Healthcare Cost and Utilization Project, representing more than 95% of the U.S. population.
With Brilacidin under mid-stage development as a novel therapy in the treatment of IBD, Cellceutix hopes the drug candidate can emerge not only as a safe and effective treatment, but also as an economical one. The need for novel non-biologic IBD therapies is considerable, as the incidence of IBD is increasing worldwide.
For additional reading on emerging therapies in IBD, click on the links below:
“Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence”
Am J Gastroenterol Suppl 2016; 3:38–44; doi:10.1038/ajgsup.2016.19
“Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms”
Gastroenterology Volume 152, Issue 2, Pages A1-A10, 309-462 (January 2017)
“Next Generation of Small Molecules in Inflammatory Bowel Disease”
Gut 2017;66:199-209 doi:10.1136/gutjnl-2016-312912
“What's in the pipeline?”
Chron’s & Colitis Foundation of America